Boston Scientific Corp (BSX)vsBrainsway Ltd (BWAY)
BSX
Boston Scientific Corp
$43.70
-1.47%
HEALTHCARE · Cap: $64.07B
BWAY
Brainsway Ltd
$9.39
-7.12%
HEALTHCARE · Cap: $406.96M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 34615% more annual revenue ($21.07B vs $60.70M). BSX leads profitability with a 16.6% profit margin vs 15.6%. BSX trades at a lower P/E of 18.6x. BSX earns a higher WallStSmart Score of 60/100 (C+).
BSX
Buy60
out of 100
Grade: C+
BWAY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.3%
Fair Value
$39.14
Current Price
$43.70
$4.56 premium
Intrinsic value data unavailable for BWAY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 35.4% year-over-year
Earnings expanding 59.8% YoY
Conservative balance sheet, low leverage
Areas to Watch
1.4% revenue growth
Distress zone — elevated risk
Earnings declined 21.5%
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 16.6% and operating margin at 19.6%. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bull Case : BWAY
The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.
Bear Case : BWAY
The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.
Key Dynamics to Monitor
BSX profiles as a value stock while BWAY is a growth play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.58 — expect wider price swings.
BWAY is growing revenue faster at 35.4% — sustainability is the question.
BSX generates stronger free cash flow (868M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (60/100 vs 51/100), backed by strong 16.6% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?